基于核酸的热带病免疫预防与治疗

[Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases].

作者信息

Ishii Ken J

机构信息

Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo.

National Institutes of Biomedical Innovation, Health and Nutrition, Center for Vaccine and Adjuvant Research.

出版信息

Yakugaku Zasshi. 2022;142(7):709-713. doi: 10.1248/yakushi.21-00210-5.

DOI:10.1248/yakushi.21-00210-5

PMID:35781498

Abstract

The number of clinical trials investigating the use of nucleic acid drugs, including DNA/RNA-based vaccines, immunostimulatory/modulatory DNA/RNA and cyclic dinucleotides, for immuno-prophylaxis and -therapy has been increasing exponentially in recent years. These new drugs have revealed their therapeutic potential not only as vaccines or adjuvant therapies, but also as monotherapies for use in immuno-therapy of cancer and allergic disease. I will present an overview of their current R&D taking place in this field, then describe our recent progress, particularly regarding CpG oligodeoxynucleotides (ODNs), such as K3, K3-SPG, and D35 as either vaccine adjuvants or mono-immunotherapeutic agents for tropical diseases including malaria and leishmaniasis.

摘要

近年来，研究使用核酸药物（包括基于DNA/RNA的疫苗、免疫刺激/调节性DNA/RNA和环二核苷酸）进行免疫预防和治疗的临床试验数量呈指数级增长。这些新药不仅作为疫苗或辅助疗法显示出治疗潜力，还作为癌症和过敏性疾病免疫治疗的单一疗法。我将概述该领域目前的研发情况，然后描述我们最近的进展，特别是关于CpG寡脱氧核苷酸（ODN），如K3、K3-SPG和D35，作为热带疾病（包括疟疾和利什曼病）的疫苗佐剂或单一免疫治疗剂的进展。